New LABA/LAMA drugs set to fracture COPD market
The drug market for chronic obstructive pulmonary disease (COPD) therapies will become more fractured as several new agents reach the market over the next decade, says a new study for health care advisory firm Decision Resources.
Two maintenance therapies currently dominate the COPD market - Boehringer Ingelheim/Pfizer’s Spiriva (tiotropium) and GlaxoSmithKline’s Advair/Seretide/Adoair (fluticasone and salmeterol). In 2011, combined sales of these therapies constituted nearly two-thirds of the COPD market. As new therapies launch, they will erode the dominance of Advair/Seretide/Adoair and Spiriva and combined market share of these two agents will fall to 12 percent in 2021.
Sales will grow to $13.3 billion in 2021 in leading markets
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
More Features in Pharmaceutical
| Headless Content Management with Blaze